Show
Sort by
-
Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients
-
- Journal Article
- A1
- open access
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis : recruitment challenges, potential bias, and statistical strategies
-
- Journal Article
- A1
- open access
Cognitive outcomes in Susac syndrome : a 2-year neuropsychological follow-up study
-
- Journal Article
- A1
- open access
Atypical clinical and novel radiological findings in Susac syndrome : experience from a large monocentric cohort
-
- Journal Article
- A1
- open access
Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis
-
- Journal Article
- A1
- open access
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
-
- Journal Article
- A1
- open access
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
-
- Journal Article
- A2
- open access
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry
-
- Journal Article
- A1
- open access
Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis
-
- Journal Article
- A1
- open access
Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation
-
- Journal Article
- A2
- open access
Concurrent ocular and cerebral toxoplasmosis in a liver transplant patient treated with anti-CD40 monoclonal antibody
-
- Journal Article
- A1
- open access
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis : results from MSBase registry
-
- Journal Article
- A1
- open access
Disability accrual in primary and secondary progressive multiple sclerosis
-
- Journal Article
- A1
- open access
Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis
-
Neuro-image: developmental venous anomaly and central vein sign in multiple sclerosis
-
- Journal Article
- A1
- open access
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
-
- Journal Article
- A1
- open access
Exome sequencing and multigene panel testing in 1,411 patients with adult-onset neurologic disorders
-
- Journal Article
- A1
- open access
Shortcutting the diagnostic odyssey : the multidisciplinary program for undiagnosed rare diseases in adults (UD-PrOZA)
-
- Journal Article
- A1
- open access
Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients
-
A unique phenotype of longitudinal extensive transverse myelitis in autoimmune lymphoproliferative syndrome
-
Lifestyle factors in multiple sclerosis disability progression and silent brain damage : a cross-sectional study
-
Prediction of multiple sclerosis outcomes when switching to ocrelizumab
-
Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis
-
Association of latitude and exposure to ultraviolet B radiation with severity of multiple sclerosis : an international registry study
-
Machine-learning-based prediction of disability progression in multiple sclerosis : an observational, international, multi-center study
-
Alemtuzumab in multiple sclerosis : a retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors
-
GAD65 autoimmune encephalitis : a cause of rapidly evolving frontotemporal atrophy
-
- Journal Article
- A1
- open access
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity : the Belgian experience
-
- Journal Article
- A1
- open access
Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2
-
- Journal Article
- A1
- open access
A clinician’s perspective on yellow fever vaccine-associated neurotropic disease
-
- Journal Article
- A1
- open access
Deciphering the morphology of motor evoked potentials
-
- Journal Article
- A1
- open access
End of dose interval symptoms in patients treated with natalizumab : a role for serum cytokines?
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder
-
Atypical clinical and novel radiological findings in Susac syndrome
-
Redefining the Multiple Sclerosis Severity Score (MSSS) : the effect of sex and onset phenotype
-
Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder
-
Indications de l’autogreffe dans la sclérose en plaques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) en lien avec la Société francophone de la sclérose en plaques
-
Cladribine in myasthenia gravis : a case urging for prudence
-
EBV-NMDA double positive encephalitis in an immunocompromised patient
-
Biotinidase deficiency: A treatable cause of opticospinal syndrome in young adults
-
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND) : a double-blind, randomised, phase 3 study
-
Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis : evaluation with brain MRI, 1H and 31P MRS, and clinical and cognitive testing
-
Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups : analysis of the global NMOBase Registry
-
A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis
-
An omics strategy to unravel the role of the β2-adrenergic receptor in inflammation
-
Adrenergic regulation of Interleukin-6 and chemokine expression : stressing NF-κB
-
- Journal Article
- A1
- open access
Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS) : study protocol for a randomized controlled trial
-
β2-Adrenergic receptors protect axons during energetic stress but do not influence basal glio-axonal lactate shuttling in mouse white matter
-
- Journal Article
- A1
- open access
β2-adrenergic agonists modulate TNF-α induced astrocytic inflammatory gene expression and brain inflammatory cell populations
-
Benign myelitis as a first presentation of systemic sarcoidosis : importance of early diagnosis and treatment